These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19775998)

  • 21. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
    Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
    Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
    Eskander RN; Tewari KS
    Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approaches in angiogenic targeting for colorectal cancer.
    Prat A; Casado E; Cortés J
    World J Gastroenterol; 2007 Nov; 13(44):5857-66. PubMed ID: 17990351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
    Asmane I; Kurtz JE; Bajard A; Guastalla JP; Meeus P; Tredan O; Labidi Galy I; Moullet I; Ardisson P; Vincent L; Coeffic D; Dufresne A; Bergerat JP; Ray-Coquard I
    Bull Cancer; 2011 Oct; 98(9):80-9. PubMed ID: 21926034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab and ovarian cancer.
    Lai GG; Penson RT
    Drugs Today (Barc); 2011 Sep; 47(9):669-81. PubMed ID: 21971541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
    Han ES; Lin P; Wakabayashi M
    Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed.
    González Martín A
    Clin Transl Oncol; 2009 Sep; 11(9):559-60. PubMed ID: 19775993
    [No Abstract]   [Full Text] [Related]  

  • 30. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug insight: antiangiogenic therapies for gastrointestinal cancers--focus on monoclonal antibodies.
    Reinacher-Schick A; Pohl M; Schmiegel W
    Nat Clin Pract Gastroenterol Hepatol; 2008 May; 5(5):250-67. PubMed ID: 18382435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
    Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
    Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
    Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
    Monk BJ; Pujade-Lauraine E; Burger RA
    Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
    Gubbi A; Kendrick JE; Finkler NJ
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Han ES; Monk BJ
    Gynecol Oncol; 2007 Apr; 105(1):3-6. PubMed ID: 17383545
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiogenesis as targeted breast cancer therapy.
    Hayes DF; Miller K; Sledge G
    Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapeutic agents in ovarian cancer.
    Collinson F; Jayson G
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):44-53. PubMed ID: 19125003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.